Immunic, Inc. (IMUX) vs Polaryx Therapeutics, Inc. Common Stock (PLYX)

A side-by-side comparison of Immunic, Inc. and Polaryx Therapeutics, Inc. Common Stock across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Immunic, Inc. logo
IMUX
Immunic, Inc.
$107M
$7.82HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Polaryx Therapeutics, Inc. Common Stock logo
PLYX
Polaryx Therapeutics, Inc. Common Stock
$105M
$2.10HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

Total return — IMUX vs PLYX

growth of $100 · dividends reinvested · last 1y
IMUX +29.1% (+29.1%/yr)PLYX -94.1% (-94.1%/yr)IMUX compounded faster over this window
Log scale — wide-divergence pair
1101001kStart $100$129$6
IMUX PLYX

IMUX vs PLYX: by the numbers

  • •IMUX is the larger company ($107M vs $105M market cap).

Metrics side by side

Valuation

MetricIMUXPLYX
P/B ratio0.839.57

Profitability

MetricIMUXPLYX
Gross margin0.00%0.00%
Operating margin0.00%0.00%
Net margin0.00%0.00%
ROE-87.45%-62.61%
ROIC-92.16%-47.75%

Growth (annualized)

MetricIMUXPLYX
Total return CAGR (5Y)-35.70%N/A

Go deeper

Full IMUX analysisFull PLYX analysisInteractive comparison tool

Dig into the metrics

Immunic ROEPolaryx Therapeutics, Inc. Common Stock ROEImmunic operating marginPolaryx Therapeutics, Inc. Common Stock operating marginImmunic revenue growthPolaryx Therapeutics, Inc. Common Stock revenue growthImmunic free cash flowPolaryx Therapeutics, Inc. Common Stock free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.